

Interim Job Aid for Monkeypox (MPV) Post Exposure Prophylaxis (PEP): Part 1- Product Information

This Job Aid is **only** for use if the Chicago Department of Public Health has already approved of administering vaccination. For questions about monkeypox (MPV) post exposure prophylaxis administration, please reach out to monkeypoxpep@cityofchicago.org.

Product Information: Jynneos Vaccine

(For further details, please see attached package insert.)

Jynneos is a live, non-replicating vaccine labeled for smallpox and monkeypox virus (MPV).

Indications and eligibility for PEP:

PEP is for individuals who:

- In consultation with the Chicago Department of Public Health, have had a high or intermediate risk exposure to a confirmed case of monkeypox,
- Have had a MPV exposure in the past 14 days.

PEP ++ is for:

Gay men, bisexual men, and other men who have sex with men, (GBMSM) and transpersons who are sexually active and have never been infected with MPV.

Preparation and Administration:

Jynneos is a suspension in a 0.5 ml vial.

- The standard regimen (FDA approved) is 0.5 ml subcutaneous administration.
- The alternative regimen (approved for emergency use on 8.9.22) is 0.1 ml intradermal administration. This allows for additional availability of vaccine to a larger population while maintaining similar immunogenicity to the SQ administration. <u>Evidence for ID</u> <u>Administration of Jynneos</u>.
- CDPH supports administration as follows:
 - 0.1ml intradermal administration (alternative regimen) for adults age 18 and over.
 - 0.5 ml subcutaneous administration (standard regimen) for minors **age 17 and younger**.
 - When using the standard regimen, there is no lower age limit
- With both routes of administration, CDPH recommends administration of 2 doses, no sooner than 28 days apart for both PEP and PEP ++



• If dose 1 was administered subcutaneously, it is appropriate to administer dose 2 intra-dermally.

Intradermal Injection Process: (See video for training.)



- For intradermal injection: use a tuberculin syringe with a 27 or 26 gauge, 1/4 to 1/2" needle with a short bevel. Always use a new, sterile needle and syringe for each injection.
- For subcutaneous injection: use sterile syringe with a 23–25 gauge, 5/8" needle.
- Injection should be administered to the volar (inner arm).
- If swelling occurs from the first to second administration, administer next dose in contralateral arm.
- If the volar forearm is not an option (e.g., heavy scarring, bilateral amputation), the upper back below the scapula may be used.
- If you do not see a wheal form, or have other questions about troubleshooting, please see <u>Vaccine Administration Errors</u> for more information.
 - Bavarian Nordic contact information:
 - Email: medical.information_US@bavarian-nordic.com
 - U.S. phone number: 1-844-422-8274
 - U.S. fax number: 1-843-422-8274



Side effects:

- Minimal side effects have been reported, but most commonly include:
 - o Injection site pain, redness, and swelling,
 - Muscle pain, headache, fatigue
 - <u>For intradermal injection</u>, higher risk of erythema, induration, itchiness, and pain at injection site, in comparison to SQ administration.
 - Patients with suspected adverse events should visit their healthcare provider, and their symptoms should be reported through <u>VAERS</u>.

Contraindications:

- If the individual has previously had a history of severe allergies, particularly to vaccines, their risk for contracting monkeypox should be evaluated.
- Side effects in individuals living with HIV and severe atopic dermatitis were comparable to those for healthy adults.
- If an individual has a history of keloid formation, it is recommended to administer subcutaneously.

Storage:

Please see updated package insert (attached).

- Jynneos may be stored at 2-8°C for up to 8 weeks. <u>NOTE: This is an update to</u> the original package insert that requires storage at -20°C
- Unpunctured vials may be stored at room temperature for 6 cumulative hours.
- Punctured vials may be stored in the refrigerator for up to 8 hours.

Direct patients to <u>Jynneos Patient Fact Sheet</u> for further Q and A.

For additional information including package inserts and sample standing orders visit: <u>CDC: Jynneos vaccine</u>



Job Aid for Healthcare Workers Administering MPV Post Exposure Prophylaxis (PEP): Part 2- Reporting

Reporting to CDPH

Prior to receipt of the vaccine, providers will be required to sign and return a "Monkeypox Virus Vaccine Provider Agreement" to CDPH, indicating their willingness to report in ICARE.


Reporting in ICARE


- If you have an HL7, the administration of Jynneos can be entered into ICARE directly from your EMR.
- Alternatively, Jynneos administration can be entered into the "Other" part of ICARE, as seen below:

Add Shots As:	Current (with lots from			
Visit 1	Visit 2	Visit 3		
06/17/2022	*	#	#	
DTP	DTP	DTP		
🗆 HIB	- HIB	HIB		
□ HAV	HAV	HAV		
- HBV	- HBV	- HBV		
□ HPV	HPV	HPV		
FLU	FLU	FLU		
□ H1N1	H1N1	H1N1		
MMR	□ MMR	MMR		
- MEN	MEN	MEN		
□ MEN-B	C MEN-B	C MEN-B		
PNE	PNE	PNE		
POL	POL	POL		
ROT	C ROT	C ROT		
🗆 Tdap	🗆 Tdap	🗆 Tdap		
🗆 Td	🗆 Td	🗆 Td		
VAR	□ VAR	□ VAR		
□ ZOS	ZOS			
COVID-19	COVID-19	COVID-19		
Other	Other	Other		
Se	lect an Action: Continue	Cancel		
Summary Details	s	łsłt	252525	757576
	Show Lots: All	○ Vfc ○ Private	O 317	
Shot Date	Group Vaccine/Lot	Provider/Vaccinator	VFC/VIS Status	Body Site/Route
	Other Other	~	 Eligibility not determined/ 	unknown [V00] 🗸



Reporting Wastage in ICARE:





Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) Copyright © 2021 Illinois Department of Public Health